Imaging-based target volume reduction in chemoradiotherapy for locally advanced non-small-cell lung cancer (PET-Plan): a multicentre, open-label, randomised, controlled trial

Autor: Grosu, A L, Weber, W, Meyer, P, Hoffmanns, H, Nestle, U, Aurisch, R, Schäfer, W, Hehr, T, Eschmann, S M, Dornoff, W, Siekmeyer, B, Trampert, L, Gademann, G, Brunner, T, Amthauer, A, Ricke, J, Pech, M, Rübe, C, Kirsch, C M, Ezzidin, S, Schmidberger, H, Schreckenberger, M, Bamberg, M, Zips, D, Bares, R, La Fougere, C, Budach, V, Brenner, W, Beck, M, Freiherr von Gumppenberg, R, Aebersold, D, Krause, T, Feldmann, H J, Hertel, A, Stüben, G, Sciuk, J, Annweiler, H, Holl, G, Oehler, W, Schlöcker, I, Baum, R, Kimmig, B, Dunst, J, Henze, E, Lützen, U, Schwaiger, M, Strehle, K, Alberti, W, Piroth, M, Tosch, M, Pötter, R, Widder, J, Herold, C, Freund, U, Momm, F, Sautter-Bihl, M L, Tatsch, K, Hildebrandt, G, Krause, B, Nestle, Ursula ^*, Schimek-Jasch, Tanja, Kremp, Stephanie, Schaefer-Schuler, Andrea, Mix, Michael, Küsters, Andreas, Tosch, Marco, Hehr, Thomas, Eschmann, Susanne Martina, Bultel, Yves-Pierre, Hass, Peter, Fleckenstein, Jochen, Thieme, Alexander, Stockinger, Marcus, Dieckmann, Karin, Miederer, Matthias, Holl, Gabriele, Rischke, H Christian, Gkika, Eleni, Adebahr, Sonja, König, Jochem, Grosu, Anca-Ligia

Publikováno v: In The Lancet Oncology April 2020 21(4):581-592

Validation of the Decipher genomic classifier in patients receiving salvage radiotherapy without hormone therapy after radical prostatectomy – an ancillary study of the SAKK 09/10 randomized clinical trial

Autor: Dal Pra, A, Ghadjar, P, Hayoz, S, Liu, V Y T, Spratt, D E, Thompson, D J S, Davicioni, E, Huang, H-C, Zhao, X, Liu, Y, Schär, C, Gut, P, Plasswilm, L, Hölscher, T, Polat, B, Hildebrandt, G, Müller, A-C, Pollack, A, Thalmann, G N, Zwahlen, D, Aebersold, D M

Publikováno v: Dal Pra, A; Ghadjar, P; Hayoz, S; Liu, V Y T; Spratt, D E; Thompson, D J S; Davicioni, E; Huang, H-C; Zhao, X; Liu, Y; Schär, C; Gut, P; Plasswilm, L; Hölscher, T; Polat, B; Hildebrandt, G; Müller, A-C; Pollack, A; Thalmann, G N; Zwahlen, D; ... (2022). Validation of the Decipher Genomic Classifier in Patients receiving Salvage Radiotherapy without Hormone Therapy after Radical Prostatectomy-An Ancillary Study of the SAKK 09/10 Randomized Clinical Trial. Annals of oncology, 33(9), pp. 950-958. Elsevier 10.1016/j.annonc.2022.05.007

The Decipher genomic classifier (GC) has shown to independently prognosticate outcomes in prostate cancer. The objective of this study was to validate the GC in a randomized phase III trial of dose-escalated salvage radiotherapy (SRT) after radical p

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f5192fd9d39303f62c68bbee115821cf
https://doi.org/10.1016/j.annonc.2022.05.007

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

MO-0544 4pi-IMRT based path-finding for dynamic trajectory radiotherapy

Autor: Mackeprang, P., Bertholet, J., Mueller, S., Guyer, G., Loebner, H. A., Frei, D., Volken, W., Eliçin, O., Aebersold, D. M., Fix, M. K., Manser, P.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::690deefb5348d4bde464cc9b6f461a34

A cost-effectiveness analysis of consolidation immunotherapy with durvalumab in stage III NSCLC responding to definitive radiochemotherapy in Switzerland

Autor: Panje, C M, Lupatsch, J E, Barbier, M, Pardo, E, Lorez, M, Dedes, K J, Aebersold, D M, Plasswilm, L, Gautschi, O, Schwenkglenks, Matthias

BACKGROUND Consolidation immunotherapy with the programmed death ligand 1 (PD-L1) inhibitor durvalumab improves survival in patients with stage III non-small-cell lung cancer responding to radiochemotherapy. The aim of this study was to assess the co

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::12b1b2ac792cbfc0e85dd09492b5f508